Clinical Trial Update: A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 study of GDC-0810 as a single agent or in combination with palbociclib and/or an LHRH agonist in women with locally advanced or metastatic estrogen …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• GDC-0810
• Palbociclib (palbociclib)

Snippet

Sponsor: Genentech, Inc. | Conditions: Breast Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2021-06-18